Every few months in the United States, another confrontation erupts between a hospital system and a private insurer. A contract breaks down, negotiations stall, and suddenly thousands of patients receive letters warning that their hospital or doctor may soon be “out of network.” On social media, politicians and pundits line up to assign blame. The arguments vary, but the question underneath is always the same: who pays, how much and for what?
From far away, these “payer disputes” can look like distant drama in a very different system. But they actually illustrate something fundamental that concerns every health system trying to modernize: why value-based healthcare, or VBHC, is more than a slogan – and why startups have a surprisingly central role to play in making it real.
At the heart of these conflicts is a misalignment that fee-for-service medicine has lived with for decades. Hospitals and clinicians are paid for activity: visits, procedures, tests. Insurers are responsible for costs. Patients want outcomes – less pain, more function, fewer frightening nights in the emergency room. When the bill grows faster than anyone expected, the system has no shared language for what has truly been bought beyond “so many procedures at such-and-such a price.”
Value-based healthcare tries to change that conversation. Instead of paying for the volume of care, it focuses on the value of care – the health gains achieved per unit of cost. On paper, it is an elegant idea. In practice, it raises a difficult question: how do we actually know whether a particular intervention, pathway or technology delivered value?
This is where technology, and especially startups, step onto the stage.
From volume to value: measuring what really matters
Traditional healthcare IT was built to document what happened: who was admitted, what was ordered, what was billed. VBHC demands something different. It requires systems that can follow patients over time, capture their experience and functioning, and connect those trajectories to the care they received. It requires data that does not only describe the hospital’s workflow, but the patient’s life.
Startups are often better positioned than large incumbents to build precisely these kinds of tools. A young company developing a digital therapy for heart failure, for example, is forced from day one to answer questions that sound very much like VBHC: how many hospitalizations can we prevent, how many days of good-quality life can we restore, how will we prove that this effect is real and repeatable? It is not enough to show a slick interface or a clever algorithm. Investors, regulators and eventually payers want to see changes in hard outcomes.
In that sense, the most interesting startups in health tech are not selling apps; they are selling ways to observe value.
Imagine a remote monitoring platform for patients with chronic obstructive pulmonary disease. In a fee-for-service world, the product might be pitched as a way to increase contact moments: more teleconsultations, more billed interactions. In a value-based world, the pitch must change. The question becomes whether the platform can reduce exacerbations, shorten hospital stays, or improve exercise tolerance and quality of life. If the answer is yes, and if the evidence is credible, the startup can enter into a very different kind of relationship with hospitals and payers: one where payment is tied to outcomes, not logins.
Why startups are crucial to making VBHC work?
For patients, the stakes are more concrete. Under value-based arrangements, their health is no longer just a narrative told in clinic notes, but a series of signals that can shape how providers are paid. Their self-reported pain, fatigue or anxiety can become part of the formal definition of success. A startup that knows how to capture those signals – not through endless surveys, but through thoughtful, often invisible design – becomes a kind of sensor for value in the system.
The appeal of VBHC is not difficult to grasp. In theory, it rewards interventions that genuinely help and discourages those that merely keep the apparatus of care busy. Yet the American payer disputes show how far reality still is from that vision. When a costly new drug or device enters the market, the conversation often begins and ends with price: the manufacturer sets a high number, the insurer pushes back, the hospital is caught in the middle. Patients watch nervously to see who will yield, knowing that their own access may be the bargaining chip.
If value-based contracts were the norm, these arguments might look different. Instead of focusing purely on list price, parties would be forced to ask what the therapy achieves in terms of survival, readmissions, functioning, or return to work, and how those achievements could be fairly shared. Some oncology drugs are already reimbursed in arrangements where the manufacturer only receives full payment if the patient survives beyond a certain threshold. Digital tools are beginning to explore similar risk-sharing models: if they fail to improve adherence, prevent complications or reduce unnecessary visits, they do not get paid in full.
Startups are important here not just as suppliers of tools, but as partners willing to accept that kind of accountability. A young company has more freedom to bake these ideas into its business model. Instead of demanding an annual license regardless of performance, it can propose hybrid arrangements: a modest platform fee combined with bonuses linked to measurable improvements in outcomes. In doing so, it aligns itself explicitly with the logic of VBHC.
The challenge, of course, is that measuring value is complicated. Outcomes unfold over months and years. Patients differ from one another in ways that matter. Not all benefits are easily captured in hospital data. There is a risk that, in the search for clarity, systems will retreat to what is easy to count: laboratory values, readmission rates, mortality. Those are important, but incomplete.
This is another place where thoughtful design and technology matter. A startup that wants to be taken seriously in value-based discussions must be able to show not only that it can collect data, but that it can collect the right data in the right way. It must be honest about uncertainty and bias. It must work with clinicians and patients to define outcomes that reflect what matters most in a given condition, not simply what is convenient.
What patients stand to gain from Value-Based models?
For health systems outside the United States, watching these payer disputes can feel like watching a storm over a distant ocean. But the same pressures are moving closer to home. Ageing populations, rising expectations, costly therapies and constrained budgets are pushing every payer – public or private – to ask how much health they are really buying with each euro or zloty. VBHC will not arrive in a single reform; it will seep in through pilot projects, innovative contracts and the quiet language of policy documents.
When that happens, startups will either be on the sidelines, selling point solutions into outdated funding models, or they will be at the table as partners in redesigning how care is paid for and delivered. The difference will depend on whether they can speak the language of value with the same fluency that they talk about user experience, AI or cloud architecture.
Value-based healthcare is often presented as an abstract framework, a diagram of arrows between boxes labelled “outcomes” and “costs.” The American conflicts between payers and providers remind us that beneath those diagrams are real people and real vulnerabilities. For a patient with cancer, diabetes or heart failure, the question is not whether the system is fee-for-service or value-based. The question is whether they will receive treatments that truly help, without being trapped in a game of financial chicken between institutions.
If value-based models help align the incentives of hospitals, payers, manufacturers and startups around that simple goal – a life lived better, at a cost that society can bear – then they are more than a management trend. They are a necessary evolution. And if startups use their agility and proximity to patients to become the instruments that make such models measurable and workable, their contribution to healthcare will reach far beyond the next glossy app or pilot project.